Pesquisar
TG Therapeutics Inc
TGTXAdicionar à lista de desejos
42.650USD
+0.110+0.26%
Fechamento 05/13, 16:00（ET）Cotações atrasadas em 15 min
6.62BValor de mercado
13.32P/L TTM
Mais detalhes de TG Therapeutics Inc Empresa
TG Therapeutics, Inc. is a fully integrated, commercial stage, biopharmaceutical company. The Company is focused on the acquisition, development, and commercialization of novel treatments for B-cell diseases. Its clinical drug candidates are Ublituximab IV (anti-CD20 mAb), Ublituximab Subcutaneous (anti-CD20 mAb), Azer-cel, TG-1701 (BTK inhibitor), and TG-1801 (anti-CD47/CD19 bispecific mAb). BRIUMVI is an anti-CD20 monoclonal antibody for the treatment of RMS, which includes clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease. TG-1701 is a novel, orally available and covalently bound Bruton’s tyrosine kinase (BTK) inhibitor that exhibits selectivity to BTK in vitro kinase screening. TG-1801 is a bispecific CD47 and CD19 antibody. It also evaluates complementary products, technologies and companies for in-licensing, partnership, acquisition, and/or investment opportunities.
Informações de TG Therapeutics Inc
Código da empresaTGTX
Nome da EmpresaTG Therapeutics Inc
Data de listagemDec 14, 1995
CEOWeiss (Michael S)
Número de funcionários338
Tipo de títulosOrdinary Share
Fim do ano fiscalDec 14
Endereço3020 Carrington Mill Blvd., Suite 475
CidadeMORRISVILLE
Bolsa de valoresNASDAQ OMX - NASDAQ BASIC
PaísUnited States of America
Código postal27560-5435
Telefone18775758489
Sitehttps://www.tgtherapeutics.com/
Código da empresaTGTX
Data de listagemDec 14, 1995
CEOWeiss (Michael S)
Executivos da empresa TG Therapeutics Inc
Nome
Nome/Posição
Posição
Ações detidas
Variação
Mr. Michael S. Weiss, J.D.
Mr. Michael S. Weiss, J.D.
Chairman of the Board, President, Chief Executive Officer
Chairman of the Board, President, Chief Executive Officer
9.78M
--
Mr. Sean A. Power
Mr. Sean A. Power
Chief Financial Officer, Treasurer, Corporate Secretary
Chief Financial Officer, Treasurer, Corporate Secretary
690.61K
--
Mr. Kenneth (Ken) Hoberman
Mr. Kenneth (Ken) Hoberman
Independent Director
Independent Director
279.65K
--
Dr. Yann Echelard
Dr. Yann Echelard
Independent Director
Independent Director
223.82K
--
Mr. Daniel Hume, J.D.
Mr. Daniel Hume, J.D.
Independent Director
Independent Director
192.75K
--
Mr. Laurence Neil (Larry) Charney, CPA
Mr. Laurence Neil (Larry) Charney, CPA
Lead Independent Director
Lead Independent Director
179.69K
--
Dr. Sagar Lonial
Dr. Sagar Lonial
Independent Director
Independent Director
94.06K
--
Nome
Nome/Posição
Posição
Ações detidas
Variação
Mr. Michael S. Weiss, J.D.
Mr. Michael S. Weiss, J.D.
Chairman of the Board, President, Chief Executive Officer
Chairman of the Board, President, Chief Executive Officer
9.78M
--
Mr. Sean A. Power
Mr. Sean A. Power
Chief Financial Officer, Treasurer, Corporate Secretary
Chief Financial Officer, Treasurer, Corporate Secretary
690.61K
--
Mr. Kenneth (Ken) Hoberman
Mr. Kenneth (Ken) Hoberman
Independent Director
Independent Director
279.65K
--
Dr. Yann Echelard
Dr. Yann Echelard
Independent Director
Independent Director
223.82K
--
Mr. Daniel Hume, J.D.
Mr. Daniel Hume, J.D.
Independent Director
Independent Director
192.75K
--
Mr. Laurence Neil (Larry) Charney, CPA
Mr. Laurence Neil (Larry) Charney, CPA
Lead Independent Director
Lead Independent Director
179.69K
--
Detalhamento da receita
Moeda: USDAtualizado em: seg, 6 de abr
Moeda: USDAtualizado em: seg, 6 de abr
FY2025
FY2025Q4
FY2025Q3
FY2025Q1
FY2024
Por EmpresaUSD
Nome
Receita
Proporção
Total product revenue, net
606.93M
98.48%
Royalty Revenue
5.62M
0.91%
Other Revenue
3.59M
0.58%
License Revenue
152.00K
0.02%
Milestone Revenue
0.00
0.00%
Os dados relevantes ainda não foram divulgados pela empresa.
Por Empresa
Por Região
Por EmpresaUSD
Nome
Receita
Proporção
Total product revenue, net
606.93M
98.48%
Royalty Revenue
5.62M
0.91%
Other Revenue
3.59M
0.58%
License Revenue
152.00K
0.02%
Milestone Revenue
0.00
0.00%
Distribuição de ações
Atualizado em: dom, 10 de mai
Atualizado em: dom, 10 de mai
Investidores
Tipos de investidores
Investidores
Investidores
Proporção
BlackRock Institutional Trust Company, N.A.
12.51%
Weiss (Michael S)
6.39%
State Street Investment Management (US)
5.54%
Vanguard Portfolio Management, LLC
5.40%
Vanguard Capital Management, LLC
4.31%
Outro
65.85%
Investidores
Investidores
Proporção
BlackRock Institutional Trust Company, N.A.
12.51%
Weiss (Michael S)
6.39%
State Street Investment Management (US)
5.54%
Vanguard Portfolio Management, LLC
5.40%
Vanguard Capital Management, LLC
4.31%
Outro
65.85%
Tipos de investidores
Investidores
Proporção
Investment Advisor
37.18%
Investment Advisor/Hedge Fund
19.01%
Hedge Fund
8.02%
Individual Investor
7.47%
Research Firm
3.77%
Pension Fund
1.23%
Bank and Trust
0.50%
Family Office
0.22%
Insurance Company
0.03%
Outro
22.56%
Participação acionária institucional
Atualizado em: qua, 1 de abr
Atualizado em: qua, 1 de abr
Período do relatório
N.º de instituições
Ações detidas
Proporção
Variação
2026Q1
760
122.50M
80.02%
+4.40M
2025Q4
733
103.04M
64.90%
-17.74M
2025Q3
698
101.46M
63.91%
-17.24M
2025Q2
693
115.94M
73.03%
-21.56M
2025Q1
704
116.82M
73.80%
-25.76M
2024Q4
657
113.87M
72.65%
-36.14M
2024Q3
598
117.83M
76.11%
-20.28M
2024Q2
544
109.58M
70.90%
-28.91M
2024Q1
535
105.41M
68.45%
-29.01M
2023Q4
542
104.64M
69.13%
-36.73M
Ver Mais
Atividade dos acionistas
Nome
Ações detidas
Proporção
Variação
Var. %
Data
BlackRock Institutional Trust Company, N.A.
19.14M
11.99%
+312.14K
+1.66%
Dec 31, 2025
Weiss (Michael S)
9.78M
6.12%
+622.00K
+6.79%
Jan 08, 2026
State Street Investment Management (US)
8.48M
5.31%
+379.38K
+4.68%
Dec 31, 2025
ClearBridge Investments, LLC
3.45M
2.16%
-1.20M
-25.76%
Dec 31, 2025
Geode Capital Management, L.L.C.
3.40M
2.13%
-40.05K
-1.16%
Dec 31, 2025
Soleus Capital Management, L.P.
3.14M
1.97%
-705.42K
-18.35%
Dec 31, 2025
Congress Asset Management Company, LLP
1.92M
1.2%
+922.41K
+92.24%
Dec 31, 2025
Pictet Asset Management Ltd.
1.46M
0.91%
-148.50K
-9.23%
Dec 31, 2025
Ver Mais
ETFs Relacionados
Atualizado em: sáb, 6 de dez
Atualizado em: sáb, 6 de dez
Nome
Proporção
Invesco S&P SmallCap Health Care ETF
2.89%
State Street SPDR S&P Biotech ETF
1.93%
Virtus LifeSci Biotech Products ETF
1.49%
Invesco S&P SmallCap 600 Pure Growth ETF
1.44%
Invesco S&P SmallCap Momentum ETF
1.4%
Direxion Daily S&P Biotech Bull 3X Shares
1.11%
State Street SPDR S&P 600 Small Cap Growth ETF
0.65%
First Trust NASDAQ Pharmaceuticals ETF
0.63%
Principal U.S. Small-Cap ETF
0.62%
Vanguard S&P Small-Cap 600 Growth Index Fund
0.61%
Ver Mais
Invesco S&P SmallCap Health Care ETF
Proporção2.89%
State Street SPDR S&P Biotech ETF
Proporção1.93%
Virtus LifeSci Biotech Products ETF
Proporção1.49%
Invesco S&P SmallCap 600 Pure Growth ETF
Proporção1.44%
Invesco S&P SmallCap Momentum ETF
Proporção1.4%
Direxion Daily S&P Biotech Bull 3X Shares
Proporção1.11%
State Street SPDR S&P 600 Small Cap Growth ETF
Proporção0.65%
First Trust NASDAQ Pharmaceuticals ETF
Proporção0.63%
Principal U.S. Small-Cap ETF
Proporção0.62%
Vanguard S&P Small-Cap 600 Growth Index Fund
Proporção0.61%
Dividendo
Um total de
0.00
USD foi distribuído em dividendos nos últimos 5 anos.
Data
Dividendo
Data de registro
Data de pagamento
Data ex-dividendo
Sem dados
Desdobramento de ações
Data
Data ex-dividendo
Tipo
Proporção
Sem dados
Data
Data ex-dividendo
Tipo
Proporção
Sem dados
